Reenie McCarthy is the Chief Executive Officer and a member of the Board of Stealth BioTherapeutics, a biopharmaceutical company developing investigational therapies to treat mitochondrial dysfunction. Reenie is a 20+ year veteran of the investment team of Morningside, Stealth’s principal investor. Reenie has extensive experience working with numerous private nonclinical and clinical stage companies developing drugs across a broad spectrum of therapeutic areas and providing operational and management oversight to venture-backed technology companies. Reenie has been involved with Stealth since 2009, before stepping into a dedicated leadership role at the company in 2015.